BridgeBio Pharma, Inc. (BBIO) NASDAQ
69.23
+1.9017(+2.82%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
69.23
+1.9017(+2.82%)
Currency In USD
| Previous Close | 67.33 |
| Open | 67.45 |
| Day High | 69.5 |
| Day Low | 66.71 |
| 52-Week High | 84.94 |
| 52-Week Low | 37.69 |
| Volume | 1.14M |
| Average Volume | 2.55M |
| Market Cap | 13.56B |
| PE | -18.51 |
| EPS | -3.74 |
| Moving Average 50 Days | 70.7 |
| Moving Average 200 Days | 66.58 |
| Change | 1.9 |
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
GlobeNewswire Inc.
Mar 11, 2026 6:00 PM GMT
- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified subgroups - Early separation from placebo observed
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
GlobeNewswire Inc.
Mar 04, 2026 12:30 PM GMT
PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data fro
BridgeBio to Participate in March Investor Conferences
GlobeNewswire Inc.
Feb 23, 2026 12:30 PM GMT
PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its manag